Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2018 · 10-K
Revenue$40.78M$40.78M+1,898.9% vs Q4 2017 Net Income$4.31M$4.31MN/M vs Q4 2017 EPS Diluted$0.11$0.11N/M vs Q4 2017 Operating Incomederived$2,450,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,140,000N/M Free Cash Flowderived-$9,029,000N/M Margins · derivedOperating margin6.0%+819.6 pt vs Q4 2017
Net margin10.6%+794.7 pt vs Q4 2017
ended Dec 31, 2018 · filed Feb 27, 2019 · 58 d after period end